27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech companies JPMorgan turned bearish on Monday.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Jessica Fye downgraded Mersana Therapeutics Inc (NASDAQ:MRSN) to Neutral and Novavax, Inc. (NASDAQ:NVAX) to Underweight.
Anupam Rama downgraded Ophthotech Corp (NASDAQ:OPHT) and Otonomy Inc (NASDAQ:OTIC) to Underweight.
The Thesis
The downgraded stocks have “compelling yet early-stage pipelines," according to JPMorgan.
“Indeed, the combination of continued innovation, a constructive FDA, ready access to capital markets, and potential (yet unpredictable) momentum on M&A tailwind presents a compelling setup for the sector as a whole,” the analysts said in a Monday note.
Not all of the stocks have coming catalysts.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Fye said she considers Mersana’s platform attractive but does not expect any stock-driving activity in 2018. JPMorgan lowered its price target for Mersana from $23 to $19 on anticipated delay in XMT-1522 dose escalation to 2019.
Novavax suffers a “precarious” financial position with net debt as management advances its earlier-stage flu programs, the analyst said. Fye sees risk that the company’s next catalyzing candidate NanoFlu may need an efficacy trial for approval, and she sees share recovery as being dependent on positive Phase 3 data for RSV maternal immunization expected in 2019.
Ophthotech is not expected to release clinical data until the end of 2018, but “it will take definitive proof-of-concept data to ascribe credit to the Zimura franchise overall,” Rama said. The analyst forecast underperformance relative to the rest of JPMorgan’s coverage universe.
Otonomy was downgraded on a lack of 2018 value drivers as the company initiates a third Phase 3 trial for Otividex and works on early-stage candidates with 2019 data.
Price Action
At the time of publication Monday, Otonomy was down 10.4 9 percent; Novavax was down 3 percent; Ophthotech was down 1.9 percent; and Mersana fell 3.5 percent.
Related Links:
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.